Biryani By Kilo, D-Mart Face Action In Maharashtra Crackdown Ahead Of Diwali
Source Entity
NDTV News Search Records Found 1000
The Maharashtra FDA conducted massive enforcement drives in late 2026, seizing over ₹63 crore in food stocks and ₹34.51 lakh in drugs and cosmetics. These actions, involving thousands of inspections and license suspensions, aimed to ensure consumer safety during the festive season.
Maharashtra FDA Launches Massive Enforcement Drive
In a significant move to safeguard public health, the Maharashtra Food and Drug Administration (FDA) executed a series of intensive enforcement drives throughout October and early November 2026. The department conducted extensive inspections across the state, resulting in the seizure of food stocks valued at ₹63.45 crore and pharmaceutical products and cosmetics worth ₹34.51 lakh. This large-scale operation highlights the state's ongoing efforts to curb the circulation of substandard products during periods of high consumer demand.
Targeting the Food Supply Chain
Between September 1 and November 3, 2026, the FDA inspected 9,667 food establishments. The severity of the findings is evidenced by the suspension of 954 food business licences and the issuance of 4,603 improvement notices. The seized goods, amounting to 3,098.46 metric tonnes, were primarily comprised of high-demand festive items. Salt, spices, and condiments led the seizures at ₹21.09 crore, followed closely by edible oils at ₹16.31 crore. Additionally, milk-based products like ghee and khava (mawa), essential for Diwali preparations, were seized to the tune of ₹7.63 crore, alongside ₹7.47 crore in dry fruits.
Crackdown on Pharmaceutical and Cosmetic Standards
Beyond food safety, the FDA intensified its oversight of the pharmaceutical sector. Throughout October 2026, the department conducted 1,986 inspections of drug manufacturing and sales establishments. The regulatory action was decisive: 122 licences were cancelled, and 422 were suspended. These measures targeted both the sales sector—where 1,694 inspections took place—and the manufacturing sector, which saw 292 targeted inspections. This dual-pronged strategy ensures that the entire lifecycle of medical products, from production to retail, remains under strict scrutiny.
The Festive Context and Consumer Protection
The timing of these operations is not incidental. The "Diwali special drive," conducted between October 15 and November 3, underscores the vulnerability of the market during peak festive seasons, where demand for sweets and snacks often leads to the proliferation of adulterated or substandard goods. By collecting 8,835 food samples for rigorous testing, the FDA is attempting to mitigate the risks of foodborne illnesses and the distribution of unsafe medicinal products during a high-consumption window.
Future Trends and Regulatory Implications
This enforcement action signals a shift toward more aggressive regulatory oversight in Maharashtra. The FDA’s decision to publicly disclose these figures and urge citizens to report illegal manufacturing or substandard goods suggests a move toward a more participatory regulatory model. Moving forward, businesses operating within the food and pharmaceutical sectors in Maharashtra can expect increased frequency of inspections and a higher threshold for compliance. The state’s focus on cancelling and suspending licenses rather than relying solely on fines indicates a "zero-tolerance" approach aimed at long-term market sanitation.
Conclusion
Ultimately, the Maharashtra FDA’s recent actions serve as a critical warning to businesses that prioritize profit over compliance. By removing significant quantities of potentially hazardous food and substandard medical products from the market, the department has reinforced its role as the primary guardian of consumer health. As the state continues to integrate public feedback into its enforcement strategies, the long-term impact is likely to be a more transparent, safer, and more regulated marketplace for all citizens.
Verification Required?